[1]罗秀林,综述,张烁,等.肾动脉去交感神经术治疗心力衰竭——希望还是炒作[J].心血管病学进展,2016,(3):268-271.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
　LUO Xiulin,ZHANG Shuo.Renal Sympathetic Denervation for Heart Failure—Hopes or Hypes[J].Advances in Cardiovascular Diseases,2016,(3):268-271.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
点击复制

肾动脉去交感神经术治疗心力衰竭——希望还是炒作()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2016年3期
页码:
268-271
栏目:
综述
出版日期:
2016-06-20

文章信息/Info

Title:
Renal Sympathetic Denervation for Heart Failure—Hopes or Hypes
作者:
罗秀林1; 综述; 张烁1; 2; 审校
1.哈尔滨医科大学研究生院,黑龙江 哈尔滨 150086; 2.哈尔滨医科大学附属第二医院心内科,黑龙江 哈尔滨 150086
Author(s):
LUO Xiulin1;  ZHANG Shuo1; 2
1.Harbin Medical University Graduate School, Harbin 150086,Heilongjiang,China; 2.Department of Cardiology, The Second Affiliated Hospital of Harbin Medical University,Harbin 150086,Heilongjiang,China
关键词:
心力衰竭;  肾动脉去交感神经术;  交感神经系统
Keywords:
Heart failure;  Renal sympathetic denervation;  Sympathetic nervous system
分类号:
R541.6
DOI:
10.16806/j.cnki.issn.1004-3934.2016.03.013
文献标志码:
A
摘要:
心力衰竭是几乎所有心脏疾病的最终转归,每年至少有100万人因此而住院,是重大的公共卫生问题。尽管药物和一些非药物的治疗改善了心力衰竭患者的症状和病死率,但仍有很大的局限性。交感神经系统长久以来就是心力衰竭的一个潜在治疗靶点,在过去的5年间,肾动脉去交感神经术已经成为一种新型的降低交感神经兴奋性的途径,许多动物实验及临床实验证明其可以改善心力衰竭症状。近来,REACH-Pilot实验初步证明了肾动脉去交感神经术用于治疗心力衰竭是可行的、潜在有效的、安全的。
Abstract:
Heart Failure(HF), is the final outcome for almost all kinds of heart diseases, which accounts for millions of people hospitalized annually, making it a highly important public health issue. Although pharmacological therapy and some non-drug treatments have been approved to improve the symptoms and survival rates in HF patients, many limitations remain. The sympathetic nervous system has long been recognized as a potential target for therapy in HF. In the past 5 years, renal sympathetic denervation has emerged as a novel approach to decrease sympathetic activity, and has been shown to significantly improve HF outcomes in both HF animal models and patients[1]. And the REACH-Pilot study has provided the initial clinical evidence that renal sympathetic denervation was feasible, potential effective, and safe in patients with HF[2].

参考文献/References:

[1] Li ZZ,Jiang H,Chen D,et al.Renal sympathetic denervation improves cardiac dysfunction in rats with chronic pressure overload[J].Physiol Res,2015,64(5):653-662.
[2] Hlaich MP,Socralous F,Hennebry S,el al.Sympathetic activation in chronic renal failure[J].J Am Soc Nephrol,2009,20:933-939.
[3] Chen PA, Luo YS, Yang J, et al.Renal sympathetic nerve activity associated with the severity of heart failure in dogs with chronic heart failure[J].J Chin Phys,2015,17(3):354-356.
[4] Kandzari DE, Bhatt DL, Sobotka PA, et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 Trial[J]. Clin Cardiol,2012,35(9):528-535.
[5] Smithwick RH,Thompson JE.Splanchnicectomy for essential hypertension:results in 1,266 cases[J].J Am Med Assoc,1953,152(16):1501-1504.
[6] Schlaich MP, Sobotka PA, Krum H, et al. Renal sympathetic-nerve ablation for uncontrolled hypertension[J]. N Eng J Med,2009,361(9):932-934.
[7] Symplicity HTN-1 Investigators,Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension:durability of blood pressure reduction out to 24 months[J].Hypertension,2011,57(5):911-917.
[8] Symplicity HTN-2 Investigators,Esler MD,Krum H,et al. Renal sympathetic denervation in patients with treatment-resistant hypertension(The Symplicity HTN-2 Trial): a randomized controlled trial[J]. Lancet,2010,376(9756):1903-1909.
[9] Brandt MC,Mahfoud F,Reda S,et al.Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension[J].J Am Coll Cardiol,2012,59(10):901-909.
[10] Clayton SC, Haack KKV, Zucker IH. Renal denervation modulates angiotensin receptor expression in the renal cortex of rabbits with chronic heart failure[J]. Am J Physiol Renal Physiol,2011,300(1):F31-39.
[11] Hu J, Li Y, Cheng W, et al.A comparison of the efficacy of surgical renal denervation and pharmacologic therapies in post-myocardial infarction heart failure[J]. PLoS One,2014,9(5):e96996.
[12] Wang X,Zhao Q,Yu S,et al. Renal sympathetic denervation suppresses ventricular substrate remodeling in a canine high-rate pacing model[J]. Zhonghua Yi Xue Za Zhi,2015,95(11):860-864.
[13] Verloop WL, Beeftink MM, Nap A,et al. Renal denervation in heart failure with normal left ventricular ejection fraction.Rationale and design of the DIASTOLE(DenervatIon of the renAI Sympathetic nervesin hearT failure with nOrmal Lv Ejection fraction)trial[J]. Eur J Heart Fail,2013,15(12):1429-1437.
[14] Clayton D, Hanchapola I, Thomas WG, et al. Structural determinants for binding to angiotensin converting enzyme 2(ACE2)and angiotensin receptors 1 and 2[J]. Front Pharmacol,2015,30(6):5.
[15] Schiller AM, Haack KK, Pellegrino PR, et al.Unilateral renal denervation improves autonomic balance in conscious rabbits with chronic heart failure[J]. Am J Physiol Regul Integr Comp Physiol,2013,305(8):R886-892.
[16] Davies JE, Manisty CH, Petraco R,et al.First-in-man safety evaluation of renal denervation for chronic systolic heart failure:primary outcome from REACH-Pilot study[J]. Int J Cardiol,2013,162(3):189-192.
[17] Patel HC, Rosen SD, Alistair L,et al.Targeting the autonomic nervous system: measuring autonomic function and novel devices for heart failure management[J]. Int J Cardiol,2013,170(2):107-117.
[18] Sakakura K,Tunev S,Yahagi K,et al.Comparison of histopathologic analysis following renal sympathetic denervation over multiple time points[J]. Circ Cardiovasc Interv,2015,8(2):e001813.
[19] Cook S, Goy JJ, Togni M. Optical coherence tomography findings in renal denervation[J]. Eur Heart J,2012,33:2992.
[20] Rippy MK, Zarins D, Barman NC, et al.Catheter-based renal sympathetic denervation:chronic preclinical evidence for renal artery safety[J]. Clin Res Cardiol,2011,100:1095-1101.

相似文献/References:

[1]丁娟,刘地川.心力衰竭与线粒体功能障碍的研究进展[J].心血管病学进展,2016,(1):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
　DING Juan,LIU Dichuan.Research Progress of Heart Failure and Mitochondrial Dysfunction[J].Advances in Cardiovascular Diseases,2016,(3):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
[2]查凤艳,综述,覃数,等.心源性恶病质发病机制的研究进展[J].心血管病学进展,2016,(3):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
　ZHA Fengyan,QIN Shu.Advances in Pathogenesis of Cardiac Cachexia[J].Advances in Cardiovascular Diseases,2016,(3):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
[3]李慧,综述,齐国先,等.老年射血分数保留的心功能不全研究进展[J].心血管病学进展,2016,(4):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
　LI Hui,QI Guoxian.Research Progress of Heart Failure with Preserved Ejection Fraction in Elderly People[J].Advances in Cardiovascular Diseases,2016,(3):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
[4]亢玉,综述,张庆,等.二尖瓣瓣叶在功能性二尖瓣反流发生机制中的角色[J].心血管病学进展,2016,(4):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
　KANG Yu,ZHANG Qing.Role of Mitral Leaflets in Pathogenesis of Functional Mitral Regurgitation[J].Advances in Cardiovascular Diseases,2016,(3):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
[5]史秀莉,张庆,喻鹏铭.心力衰竭患者运动训练方式及其疗效的研究进展[J].心血管病学进展,2015,(5):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
　SHI Xiuli,ZHANG Qing,YU Pengming.Exercise Training Modalities and Their Treatment Effects on Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2015,(3):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
[6]熊卓超,陈康玉,严激.无创血流动力学评价在心力衰竭中的应用进展[J].心血管病学进展,2019,(6):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
　XIONG Zhuochao,CHEN Kangyu,YAN Ji.Application Progress of Noninvasive Hemodynamic Evaluation in Heart Failure[J].Advances in Cardiovascular Diseases,2019,(3):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
[7]高薇 陈伟.铁过载性心肌病[J].心血管病学进展,2019,(5):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
　GAO WeiCHEN Wei.Iron Overload Cardiomyopathy[J].Advances in Cardiovascular Diseases,2019,(3):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
[8]何燕 刘育.C型利钠肽与心力衰竭[J].心血管病学进展,2019,(5):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
　HE Yan,LIU Yu.C-type Natriuretic Peptide and Heart Failure[J].Advances in Cardiovascular Diseases,2019,(3):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
[9]吴彤 高东来.心房颤动合并心力衰竭的射频消融治疗[J].心血管病学进展,2019,(5):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]
　WU TongGAO Donglai.Catheter Ablation of Atrial Fibrillation in Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2019,(3):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]
[10]方砚 王效浣 郭朝霞.血流介导性血管扩张评价心血管病患者肱动脉内皮功能的研究进展[J].心血管病学进展,2019,(5):793.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.032]
　FANG Yan,WANG Xiaohuan,GUO Zhaoxia.Flow- mediated Vasodilation Evaluation of Brachial Artery Endothelial Function in Patients with Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(3):793.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.032]

备注/Memo

备注/Memo:
作者简介:罗秀林(1990—),在读硕士,主要从事心力衰竭的治疗研究。Email: luoxiulin922926@126.com 通信作者:张烁(1968—),主任医师,教授,博士,主要从事病毒性心肌病的治疗及发病机制、起搏及电生理研究。Email: zhangshuoemail@163.com
更新日期/Last Update: 2016-05-25